PVSG and WHO vs European Clinical, Molecular and Pathological Criteria for prefibrotic myeloproliferative neoplasms

doi:10.5315/wjh.v2.i3.71

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 3

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12135)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-10) series, Tables (1-6) series.

Item

Count

PDF

818

HTML

8548

Figures (1-10)

313

Tables (1-6)

237

Sum=9916

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1286

Download

933

Sum=2219

Aug 6, 2013 (publication date) through Apr 22, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Hematology

ISSN

2218-6204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hematol. Aug 6, 2013; 2(3): 71-88
Published online Aug 6, 2013. doi: 10.5315/wjh.v2.i3.71

Full Size Figure Download Figure

Figure 4 JAK2^V617F mutated essential thrombocythemia due to megakaryocytic, granulocytic myeloproliferation with slight splenomegaly (spleen 16 cm on echogram) and a hypercellular megakaryocytic granulocytic bone marrow and clusteried pleomorphic clumpsy megakaryocytes with dysmorphic (not cloud-like) nuclei: prefibrotic essential thrombocythemia due to megakaryocytic, granulocytic myeloproliferation. A-C: JAK2^V617-positive essential thrombocythemia due to megakaryocytic, granulocytic myeloproliferation (ET.MGM) featured by hypercellular ET due to increased megakaryocytic granulocytic myeloproliferation and the presence of pleomorphic/dysmorphic megakaryocytes (not cloud-like); D: Reticulin fibrosis grade 1, myelofibrosis grade 0.

Citation: Michiels JJ, Berneman Z, Schroyens W, Lam KH, De Raeve H. PVSG and WHO vs European Clinical, Molecular and Pathological Criteria for prefibrotic myeloproliferative neoplasms. World J Hematol 2013; 2(3): 71-88
URL: https://www.wjgnet.com/2218-6204/full/v2/i3/71.htm
DOI: https://dx.doi.org/10.5315/wjh.v2.i3.71